iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
Clinical evidence demonstrates ProFound Detection
Read moreClinical evidence demonstrates ProFound Detection
Read moreNEW YORK, Feb.
Read moreSAN DIEGO, Feb.
Read moreSOUTH SAN FRANCISCO, Calif., Feb.
Read moreMix of Level 2 and Level 3 EV Chargers Planned for
Read moreMy Broker One is Setting the Global Standard: MyBr
Read moreVocational Evaluation Services Meet Growing Demand
Read moreMINNEAPOLIS, Feb.
Read more~ Presented promising clinical update from U.S.
Read moreCONSHOHOCKEN, Pa., Feb.
Read more